USFDA30 Oct 2026, 03:23 pm
Alkem Labs API Facility Inspection Concludes With No US FDA Observations
AI Summary
Alkem Laboratories Ltd announced that its Active Pharmaceutical Ingredient (API) manufacturing facility located in Mandva underwent an inspection by the US Food and Drug Administration (US FDA). The inspection took place from October 26th to October 30th, 2026. The company has confirmed that the inspection concluded with no Form 483 observations, indicating compliance with regulatory standards. This positive outcome is crucial for maintaining the facility's ability to supply products to the US market.
Key Highlights
- US FDA inspection completed at Mandva API facility.
- Inspection concluded with zero Form 483 observations.
- Facility compliance with US FDA standards confirmed.
- Positive outcome supports continued market access.
Price Impact
More from ALKEM